I. Islam

发表

Discovery of selective urokinase plasminogen activator (uPA) inhibitors as a potential treatment for multiple sclerosis.

M. Adler, M. Whitlow, C. Mallari, 2018, Bioorganic & medicinal chemistry letters.

Structures of potent selective peptide mimetics bound to carboxypeptidase B.

M. Adler, M. Whitlow, J. Morser, 2008, Acta crystallographica. Section D, Biological crystallography.

A novel P2Y12 adenosine diphosphate receptor antagonist that inhibits platelet aggregation and thrombus formation in rat and dog models

C. Mallari, R. Vergona, W. Dole, 2007, Thrombosis and Haemostasis.

Synthesis of new urease enzyme inhibitors as antiulcer drug and computational study

N. Uddin, I. Islam, F. Rahim, 2021, Journal of biomolecular structure & dynamics.

Novel P2Y12 adenosine diphosphate receptor antagonists for inhibition of platelet aggregation (I): in vitro effects on platelets.

J. Morser, I. Islam, Shendong Yuan, 2008, Thrombosis research.

Indolinone based phosphoinositide-dependent kinase-1 (PDK1) inhibitors. Part 2: optimization of BX-517.

M. Adler, M. Whitlow, R. Feldman, 2007, Bioorganic & medicinal chemistry letters.

Why do SARS-COV vaccines not exist? The pharma scientific intelligence and business model must be revisited!

I. Islam, M. Boudjelal, Atef Nehdi, 2020, Expert opinion on drug discovery.

Identification and Characterization of a Potent, Selective, and Orally Active Antagonist of the CC Chemokine Receptor-1*

D. Taub, S. Harvey, R. Horuk, 2000, The Journal of Biological Chemistry.

Species selectivity of a small molecule antagonist for the CCR1 chemokine receptor.

R. Horuk, P. Kretschmer, M. Morrissey, 2000, European journal of pharmacology.

Reversible, orally available ADP receptor (P2Y12) antagonists Part I: Hit to lead process.

Wei Xu, M. Morrissey, I. Islam, 2018, Bioorganic & medicinal chemistry letters.

Structure-activity studies of antitumor agents based on pyrrolo[1,2-a]benzimidazoles: new reductive alkylating DNA cleaving agents.

D. Alberts, R. Dorr, I. Islam, 1991, Journal of medicinal chemistry.

BMS-986163, a Negative Allosteric Modulator of GluN2B with Potential Utility in Major Depressive Disorder.

J. Macor, A. Mathur, B. Srikumar, 2018, ACS medicinal chemistry letters.

A Non-peptide Functional Antagonist of the CCR1 Chemokine Receptor Is Effective in Rat Heart Transplant Rejection*

C. Weber, A. Krensky, H. Gröne, 2001, The Journal of Biological Chemistry.

A novel inhibitor of activated thrombin activatable fibrinolysis inhibitor (TAFIa) – Part II: Enhancement of both exogenous and endogenous fibrinolysis in animal models of thrombosis

R. Vergona, M. Nagashima, W. Dole, 2006, Thrombosis and Haemostasis.

Discovering biological efficacy of new thiadiazole as effective inhibitors of urease, glycation, and (DPPH) scavengers: biochemical and in silico study

N. Uddin, I. Islam, F. Rahim, 2022, Journal of Molecular Structure.

CCR1-specific non-peptide antagonist: efficacy in a rabbit allograft rejection model.

R. Horuk, M. Morrissey, H. Perez, 2001, Immunology letters.

Structure-activity studies of benzimidazole-based DNA-cleaving agents. Comparison of benzimidazole, pyrrolobenzimidazole, and tetrahydropyridobenzimidazole analogues.

I. Islam, E. B. Skibo, M. J. Heileman, 1994, Journal of medicinal chemistry.

Effect of Fluorination on the Polymorphism and Photomechanical Properties of Cinnamalmalononitrile Crystals

Zachary S. Gardner, G. Beran, R. Al‐Kaysi, 2022, Crystal Growth & Design.

Synthesis of indole derivatives as Alzheimer inhibitors and their molecular docking study.

N. Uddin, A. Rehman, M. Nawaz, 2022, Journal of biomolecular structure & dynamics.

KAIMRC’S Second Therapeutics Discovery Conference

Bahauddeen M. Alrfaei, W. Yue, S. Gul, 2020, Proceedings.

The Organic Chemistry of the Pyrrolo[1,2-a]benzimidazole Antitumor Agents. An Example of Rational Drug Design

I. Islam, E. B. Skibo, L. Bess, 1996 .

Pyrrolo[1,2-a]benzimidazole-based quinones and iminoquinones. The role of the 3-substituent on cytotoxicity.

I. Islam, E. B. Skibo, W. Schulz, 1995, Journal of medicinal chemistry.

Effect of halogen substitution on energies and dynamics of reversible photomechanical crystals based on 9-anthracenecarboxylic acid

G. Beran, R. Al‐Kaysi, C. Bardeen, 2021, CrystEngComm.

Identification and Characterization of Small Molecule Functional Antagonists of the CCR1 Chemokine Receptor*

D. Taub, Wei Zheng, R. Horuk, 1998, The Journal of Biological Chemistry.

Evaluation of a vitamin-cloaking strategy for oligopeptide therapeutics: biotinylated HIV-1 protease inhibitors.

R. Borchardt, J. Fisher, K. Ng, 1994, Journal of medicinal chemistry.

Synthesis and Physical Studies of Azamitosene and Iminoazamitosene Reductive Alkylating Agents. Iminoquinone Hydrolytic Stability, syn/anti-Isomerization, and Electrochemistry.

I. Islam, E. B. Skibo, 1990 .

Distinct Mechanisms of Cytotoxicity in Novel Nitrogenous Heterocycles: Future Directions for a New Anti-Cancer Agent

I. Islam, Rizwan Ali, Z. Alehaideb, 2022, Molecules.

Synthesis and physical studies of azamitosene and iminoazamitosene reductive alkylating agents. Iminoquinone hydrolytic stability, syn/anti isomerization, and electrochemistry

I. Islam, E. B. Skibo, 1990 .

Indolinone based phosphoinositide-dependent kinase-1 (PDK1) inhibitors. Part 1: design, synthesis and biological activity.

M. Adler, M. Whitlow, R. Feldman, 2007, Bioorganic & medicinal chemistry letters.

An insight into the biological activity and structure-based drug design attributes of sulfonylpiperazine derivatives

C. Supuran, I. Islam, Suryakant B. Sapkal, 2023, Journal of Molecular Structure.

Discovery of novel non-peptide CCR1 receptor antagonists.

R. Horuk, M. Morrissey, H. Perez, 1999, Journal of medicinal chemistry.

Crystal structures of potent thiol-based inhibitors bound to carboxypeptidase B.

M. Adler, M. Whitlow, I. Islam, 2005, Biochemistry.

A novel inhibitor of activated thrombin-activatable fibrinolysis inhibitor (TAFIa) – Part I: Pharmacological characterization

R. Vergona, M. Nagashima, J. Morser, 2006, Thrombosis and Haemostasis.

Discovery of potent and selective small molecule NPY Y5 receptor antagonists.

I. Islam, J. Salon, M. Walker, 2002, Bioorganic & medicinal chemistry letters.

Design, synthesis and SAR of a series of 2-substituted 4-amino-quinazoline neuropeptide Y Y5 receptor antagonists.

S. Whitebread, I. Islam, J. Zhang, 2000, Bioorganic & medicinal chemistry letters.

Using in silico modelling and FRET-based assays in the discovery of novel FDA-approved drugs as inhibitors of MERS-CoV helicase

S. Gul, I. Islam, A. Mashhour, 2021, SAR and QSAR in environmental research.

Modeling the G-protein-coupled neuropeptide Y Y1 receptor agonist and antagonist binding sites.

T. Branchek, R. Weinshank, P. Vaysse, 1997, Protein engineering.

3-Mercaptopropionic acids as efficacious inhibitors of activated thrombin activatable fibrinolysis inhibitor (TAFIa).

M. Adler, M. Whitlow, R. Vergona, 2007, Bioorganic & medicinal chemistry letters.

Molecular Crystal Microcapsules: Formation of Sealed Hollow Chambers via Surfactant Mediated Growth.

R. Al‐Kaysi, C. Bardeen, I. Islam, 2020, Angewandte Chemie.

Discovery of Zafirlukast as a novel SARS-CoV-2 helicase inhibitor using in silico modelling and a FRET-based assay

H. Alhadrami, A. Tolah, I. Islam, 2021, SAR and QSAR in environmental research.

Identification and Characterization of a Potent, Selective Nonpeptide Agonist of the CC Chemokine Receptor CCR8

R. Doms, C. Martínez-A, L. Kremer, 2006, Molecular Pharmacology.

Identification and Characterization of a Potent , Selective Nonpeptide Agonist of the CC Chemokine Receptor CCR 8

R. Doms, C. Martínez-A, L. Kremer, 2005 .

Molecular Crystal Microcapsules: Formation of Sealed Hollow Chambers via Surfactant‐Mediated Growth

R. Al‐Kaysi, C. Bardeen, I. Islam, 2020, Angewandte Chemie.

Preclinical Characterization of (R)-3-((3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one (BMS-986169), a Novel, Intravenous, Glutamate N-Methyl-d-Aspartate 2B Receptor Negative Allosteric Modulator with Potential in Major Depressive Disorder

J. Macor, A. Mathur, B. Srikumar, 2017, The Journal of Pharmacology and Experimental Therapeutics.